SATA-8505 Does Not Impact USA300 Growth in Human Blood.

Abstract

<p>(a) Hourly quantification of starting culture of 10<sup>6</sup> CFU USA300 in three parts TSB and one part whole blood from healthy donor or a patient with CGD, grown with or without 10<sup>8</sup> PFU SATA-8505 in duplicate. (b) Regrowth of surviving colonies from whole blood culture run in triplicate. One colony of <i>S</i>. <i>aureus</i> previously grown in 3:1 TSB:Whole blood without phage was subsequently grown in TSB with SATA-8505 (TSB/Phage) or without phage (TSB/TSB); one colony of the surviving <i>S</i>. <i>aureus</i> previously grown in the presence of SATA-8505 was subsequently grown in TSB with SATA-8505 (Phage/Phage) or without phage (Phage/TSB). (c) Average quantification of starting culture of 10<sup>10</sup> CFU of USA300 grown in either 3:1 TSB:Whole blood or 3:1 TSB:HBSS, with or without 10<sup>7</sup> PFU SATA-8505. (d) Average quantification of starting culture of 10<sup>7</sup> CFU of USA300 grown in three parts TSB with either one part whole blood, HBSS, serum, or peripheral mononuclear cells (PBMC) in equivalent volume HBSS. Data shown are representative of 2–3 independent experiments using 3 or more different healthy volunteers and 2 patients with CGD. Data is displayed as mean + s.e.m. ** = p<0.01.</p

    Similar works

    Full text

    thumbnail-image

    Available Versions